TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Behandling av Keratoconus Med "Cornea Collagen Cross-linking" Uten Hornhinneepitelfjerning
Brief Summary: Transepithelial CXL (performed without epithelial removal) seem to have similar clinical effect on keratoconic eyes compared to the standard CXL (which includes epithelial removal). The current study attempts to prove that hypothesis.

A prospective, controlled, randomized, contralateral trial, will involve one eye of the patient to be treated with transepithelial CXL, while the control eye will be treated with the standard CXL. Totally 20 patients (age \>18 and \<40 years) referred by an ophthalmologist to the eye department of the University Hospital North Norway for CXL treatment of bilateral progressive keratoconus, will be recruited.


Options:
A: Arm Label: Epithelium on; Type: ACTIVE_COMPARATOR; Interventions: Drug: CXL | Arm Label: Epithelium off; Type: ACTIVE_COMPARATOR; Interventions: Drug: CXL | Intervention Type: DRUG; Name: CXL; Assigned to Arm(s): Epithelium off, Epithelium on
B: Arm Label: Transepithelial accelerated cross-linking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: corneal cross-linking | Arm Label: Epithelium-off accelerated cross-linking; Type: ACTIVE_COMPARATOR; Interventions: Procedure: corneal cross-linking | Intervention Type: PROCEDURE; Name: corneal cross-linking; Assigned to Arm(s): Epithelium-off accelerated cross-linking, Transepithelial accelerated cross-linking
C: Arm Label: CXL without epithelial removal; Type: EXPERIMENTAL; Interventions: Procedure: CXL without epithelial removal | Arm Label: CXL with epithelial removal; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CXL with epithelial removal | Intervention Type: PROCEDURE; Name: CXL without epithelial removal; Assigned to Arm(s): CXL without epithelial removal | Intervention Type: PROCEDURE; Name: CXL with epithelial removal; Assigned to Arm(s): CXL with epithelial removal
D: Arm Label: Riboflavin 0.1% eyedrops every 5 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Device: UVX light | Arm Label: Riboflavin 0.1% eyedrops every 2 minutes; Type: ACTIVE_COMPARATOR; Interventions: Drug: Riboflavin, Device: UVX light | Intervention Type: DRUG; Name: Riboflavin; Assigned to Arm(s): Riboflavin 0.1% eyedrops every 2 minutes, Riboflavin 0.1% eyedrops every 5 minutes | Intervention Type: DEVICE; Name: UVX light; Assigned to Arm(s): Riboflavin 0.1% eyedrops every 2 minutes, Riboflavin 0.1% eyedrops every 5 minutes

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Centre, Randomised, Double Blind, Phase 1 Study of the Safety, Tolerability, and Immunogenicity of an Influenza Vaccine Candidate (FLU-v)
Brief Summary: The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects. The study is also designed to evaluate four different dose formulations of the vaccine to see which gives the best immune response.


Options:
A: Arm Label: Trivalent Influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent Influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
B: Arm Label: Trivalent influenza vaccine; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent influenza vaccine | Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline | Intervention Type: BIOLOGICAL; Name: Trivalent influenza vaccine; Assigned to Arm(s): Trivalent influenza vaccine | Intervention Type: BIOLOGICAL; Name: Normal saline; Assigned to Arm(s): Normal saline
C: Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccine (FLU-v) | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccine (FLU-v) | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccine (FLU-v) | Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Influenza vaccine (FLU-v) | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: FLU-v Control | Intervention Type: BIOLOGICAL; Name: Influenza vaccine (FLU-v); Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4 | Intervention Type: BIOLOGICAL; Name: FLU-v Control; Assigned to Arm(s): Control Group
D: Arm Label: vaccine; Type: EXPERIMENTAL; Interventions: Biological: Non-adjuvanted A(H1N1)v influenza vaccine | Intervention Type: BIOLOGICAL; Name: Non-adjuvanted A(H1N1)v influenza vaccine; Assigned to Arm(s): vaccine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema
Brief Summary: The purpose of this study is to assess the procedural and post-procedural safety and efficacy of AeriSeal therapy at up to 4 subsegments during a single treatment session in patients with GOLD Stage III/IV homogeneous or heterogeneous emphysema.


Options:
A: Arm Label: permanent Coil(s) implant, QOL measure; Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC), Device: Coils | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC); Assigned to Arm(s): permanent Coil(s) implant, QOL measure | Intervention Type: DEVICE; Name: Coils; Assigned to Arm(s): permanent Coil(s) implant, QOL measure
B: Arm Label: BLVR Treatment; Type: EXPERIMENTAL; Interventions: Biological: BLVR Treatment | Intervention Type: BIOLOGICAL; Name: BLVR Treatment; Assigned to Arm(s): BLVR Treatment
C: Intervention Type: DEVICE; Name: AeriSeal System; Assigned to Arm(s): N/A
D: Arm Label: BTVA; Type: EXPERIMENTAL; Interventions: Device: BTVA System | Intervention Type: DEVICE; Name: BTVA System; Assigned to Arm(s): BTVA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.


Options:
A: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15
B: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
C: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Oral contraceptives--ethinyl estradiol, levonorgestrel | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral contraceptives--ethinyl estradiol, levonorgestrel | Intervention Type: DRUG; Name: Oral contraceptives--ethinyl estradiol, levonorgestrel; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label, Randomized, Parallel Group, Study of Efficacy and Safety of a Transdermal Contraceptive Delivery System (TCDS) in Comparison to a Low-dose Oral Contraceptive Containing 0.02 mg EE and 0.1 mg LNG in a 21-day Regimen.
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.


Options:
A: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane
B: Arm Label: study drug; Type: EXPERIMENTAL; Interventions: Drug: Norethindrone acetate/ethinyl estradiol | Intervention Type: DRUG; Name: Norethindrone acetate/ethinyl estradiol; Assigned to Arm(s): study drug
C: Arm Label: AG200-15 (cycles 1-13); Type: EXPERIMENTAL; Interventions: Drug: AG200-15 (cycles 1-13) | Arm Label: Lessina crossover to AG200-15; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lessina crossover to AG200-15 | Intervention Type: DRUG; Name: AG200-15 (cycles 1-13); Assigned to Arm(s): AG200-15 (cycles 1-13) | Intervention Type: DRUG; Name: Lessina crossover to AG200-15; Assigned to Arm(s): Lessina crossover to AG200-15
D: Arm Label: Normal Weight group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Arm Label: Obese group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low dose formulation, Drug: High dose formulation | Intervention Type: DRUG; Name: Low dose formulation; Assigned to Arm(s): Normal Weight group, Obese group | Intervention Type: DRUG; Name: High dose formulation; Assigned to Arm(s): Normal Weight group, Obese group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Bifidobacteria infantis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacteria infantis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacteria infantis; Assigned to Arm(s): Bifidobacteria infantis | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
C: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
B: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Experimental Formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: HMO supplement | Arm Label: Control Formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo comparator | Intervention Type: DIETARY_SUPPLEMENT; Name: HMO supplement; Assigned to Arm(s): Experimental Formula | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo comparator; Assigned to Arm(s): Control Formula
D: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Arm Label: group 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: nutrition | Arm Label: group 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: nutrition; Assigned to Arm(s): group 1, group 2
B: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Progressive Feeding without MEF; Type: EXPERIMENTAL; Interventions: Other: Progressive Feeding without MEF | Arm Label: Progressive Feeding with MEF; Type: ACTIVE_COMPARATOR; Interventions: Other: Progressive Feeding with MEF | Intervention Type: OTHER; Name: Progressive Feeding without MEF; Assigned to Arm(s): Progressive Feeding without MEF | Intervention Type: OTHER; Name: Progressive Feeding with MEF; Assigned to Arm(s): Progressive Feeding with MEF
D: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Immunogenicity of Candidate Tuberculosis (TB) Vaccine MVA85A Administered by the Intramuscular Route and the Intradermal Route: a Phase I Randomised Active Controlled Trial
Brief Summary: This is a phase I study that will compare the safety and immunogenicity of candidate tuberculosis (TB) vaccine MVA85A administered by the intramuscular route and the intradermal route in healthy adult individuals who have been previously vaccinated with Bacillus Calmette-Guerin (BCG).


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: MVA 85A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: MVA 85A | Intervention Type: BIOLOGICAL; Name: MVA 85A; Assigned to Arm(s): Group A, Group B
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Biological: BCG: 100 microlitres ~ 2-8 x 105 pfu | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Biological: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu | Intervention Type: BIOLOGICAL; Name: BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group A, Group C | Intervention Type: BIOLOGICAL; Name: MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu; Assigned to Arm(s): Group B, Group D
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Biological: MVA 85A | Intervention Type: BIOLOGICAL; Name: MVA 85A; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: MVA85A | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Biological: Prevenar | Intervention Type: BIOLOGICAL; Name: MVA85A; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: BIOLOGICAL; Name: Prevenar; Assigned to Arm(s): 5

Answer: A